导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.68% | 1837/4773 |
| 近一周 | -3.13% | 3728/5462 |
| 近一月 | -9.86% | 4893/5421 |
| 近一季 | -18.45% | 4704/5209 |
| 近半年 | -1.25% | 1529/4920 |
| 近一年 | 6.04% | 1514/4366 |
| 近两年 | 107.01% | 523/2954 |
| 近三年 | 64.57% | 381/2253 |
| 成立以来 | 98.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.80% 1969/4961 |
34.80% 946/5312 |
- - |
- - |
| 2025 | 48.85% 509/4813 |
-1.32% 2635/3635 |
3.24% 1087/4076 |
47.64% 442/4524 |
-1.03% 2792/4813 |
| 2024 | 14.10% 1075/3463 |
-3.48% 1507/2808 |
-6.08% 1850/3014 |
27.64% 213/3129 |
-1.38% 1678/3463 |
| 2023 | -16.48% 1685/2656 |
2.32% 1377/2280 |
-6.66% 1683/2385 |
-8.14% 1667/2515 |
-4.81% 1180/2655 |
| 2022 | -26.71% 1427/2207 |
-18.65% 1367/1919 |
6.21% 752/2016 |
-17.32% 1584/2113 |
2.60% 885/2208 |
| 2021 | 16.02% 284/1822 |
-6.04% 972/1255 |
26.55% 68/1330 |
-5.28% 791/1466 |
3.02% 484/1822 |
| 2020 | - - |
- - |
- - |
6.65% 821/1164 |
15.40% 209/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 东财创业板A VS. 长安沪深300非周期A(740101) |